Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Locally Advanced Non-small Cell Lung Cancer”

170 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 170 results

Large-scale testing (Phase 3)Ended earlyNCT04866017
What this trial is testing

Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
BeiGene 63
Testing effectiveness (Phase 2)Ended earlyNCT00271323
What this trial is testing

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Who this might be right for
Non-Small-Cell Lung Carcinoma
Sanofi 14
Not applicableStudy completedNCT03645330
What this trial is testing

Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Who this might be right for
Non-small-Cell Lung Cancer
Chugai Pharmaceutical 1,026
Testing effectiveness (Phase 2)Study completedNCT03822351
What this trial is testing

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Who this might be right for
Stage III Non-small Cell Lung CancerUnresectable
MedImmune LLC 189
Testing effectiveness (Phase 2)Active Not RecruitingNCT07632365
What this trial is testing

Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLocally Advanced Non-Small Cell Lung CancerUnresectable Stage III NSCLC
Shanghai Chest Hospital 30
Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Large-scale testing (Phase 3)WithdrawnNCT00055887
What this trial is testing

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Spectrum Pharmaceuticals, Inc
Early research (Phase 1)Not Yet RecruitingNCT07523464
What this trial is testing

Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC

Who this might be right for
Locally-Advanced Non-Small Cell Lung CancerRadiotherapy
Anhui Provincial Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07287995
What this trial is testing

ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 428
Testing effectiveness (Phase 2)UnknownNCT05414630
What this trial is testing

Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Stage III
Anhui Provincial Cancer Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00682383
What this trial is testing

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Unresectable Locally Advanced NSCLC
Mt. Sinai Medical Center, Miami 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04579380
What this trial is testing

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Who this might be right for
Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer 217
Very early researchStudy completedNCT05873439
What this trial is testing

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

Who this might be right for
Nonsmall Cell Lung CancerNonsmall Cell Lung Cancer, Stage IINonsmall Cell Lung Cancer Stage III+1 more
H. Lee Moffitt Cancer Center and Research Institute 3
Testing effectiveness (Phase 2)Study completedNCT03679767
What this trial is testing

INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Who this might be right for
Metastatic Non-small Cell Lung CancerLocally Advanced Urothelial CancerMetastatic Urothelial Cancer+4 more
Incyte Corporation 121
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Early research (Phase 1)Active Not RecruitingNCT05867303
What this trial is testing

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Who this might be right for
MelanomaUrothelial CarcinomaRenal Cell Carcinoma+3 more
RemeGen Co., Ltd. 48
Early research (Phase 1)Study completedNCT00921739
What this trial is testing

Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

Who this might be right for
Non Small Cell Lung CancerSmall Cell Lung CancerThymoma+1 more
Duke University 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06472076
What this trial is testing

Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 88
Testing effectiveness (Phase 2)Study completedNCT00191490
What this trial is testing

Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 162
Testing effectiveness (Phase 2)Ended earlyNCT02147990
What this trial is testing

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 318
Load More Results